PriceTargets.com logo

Teva Pharmaceutical Industries - TEVA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $37.67
  • Forecasted Upside: 14.59%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$32.87 As of 03/4/2026 04:59 PM ET
▲ +0.59 (1.83%)

This chart shows the closing price for TEVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Teva Pharmaceutical Industries Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TEVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TEVA

Analyst Price Target is $37.67
▲ +14.59% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Teva Pharmaceutical Industries in the last 3 months. The average price target is $37.67, with a high forecast of $45.00 and a low forecast of $26.00. The average price target represents a 14.59% upside from the last price of $32.87.

This chart shows the closing price for TEVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 investment analysts is to moderate buy stock in Teva Pharmaceutical Industries. This rating has held steady since January 2026, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/4/2026

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/4/2026Piper SandlerReiterated RatingOverweight ➝ Overweight$40.00 ➝ $41.00
2/18/2026Truist FinancialBoost TargetBuy ➝ Buy$38.00 ➝ $42.00
2/9/2026The Goldman Sachs GroupBoost TargetBuy ➝ Buy$36.00 ➝ $45.00
1/30/2026BarclaysBoost TargetOverweight ➝ Overweight$35.00 ➝ $38.00
1/29/2026Truist FinancialBoost TargetBuy ➝ Buy$36.00 ➝ $38.00
1/29/2026ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$35.00 ➝ $40.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/6/2026Jefferies Financial GroupBoost TargetBuy ➝ Buy$29.00 ➝ $40.00
12/22/2025Piper SandlerBoost TargetOverweight ➝ Overweight$30.00 ➝ $40.00
12/19/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$31.00 ➝ $35.00
12/16/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$28.00 ➝ $35.00
12/9/2025Bank of AmericaBoost TargetBuy ➝ Buy$29.00 ➝ $32.00
12/9/2025BarclaysInitiated CoverageOverweight$35.00
12/8/2025BarclaysUpgradeStrong-Buy
12/8/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$28.00 ➝ $31.00
12/5/2025ScotiabankInitiated CoverageSector Outperform$35.00
11/6/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$26.00 ➝ $28.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/3/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$23.00 ➝ $26.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/24/2025UBS GroupBoost TargetBuy ➝ Buy$23.00 ➝ $26.00
6/26/2025UBS GroupLower TargetBuy ➝ Buy$24.00 ➝ $23.00
6/6/2025The Goldman Sachs GroupInitiated CoverageBuy$24.00
5/28/2025Truist FinancialInitiated CoverageBuy$25.00
5/27/2025Truist FinancialUpgradeStrong-Buy
5/12/2025JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$21.00 ➝ $23.00
5/8/2025Bank of AmericaBoost TargetBuy ➝ Buy$20.00 ➝ $22.00
4/28/2025HSBCUpgradeStrong-Buy
3/6/2025Bank of AmericaLower TargetBuy ➝ Buy$23.00 ➝ $20.00
1/30/2025UBS GroupLower TargetBuy ➝ Buy$30.00 ➝ $27.00
1/30/2025BarclaysLower TargetOverweight ➝ Overweight$28.00 ➝ $26.00
1/23/2025UBS GroupBoost TargetBuy ➝ Buy$28.00 ➝ $30.00
1/17/2025Piper SandlerBoost TargetOverweight ➝ Overweight$23.00 ➝ $30.00
12/18/2024BarclaysBoost TargetOverweight ➝ Overweight$25.00 ➝ $28.00
10/23/2024BarclaysBoost TargetOverweight ➝ Overweight$22.00 ➝ $25.00
10/21/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$16.00 ➝ $18.00
9/3/2024UBS GroupBoost TargetBuy ➝ Buy$24.00 ➝ $26.00
8/1/2024BarclaysBoost TargetOverweight ➝ Overweight$21.00 ➝ $22.00
7/10/2024UBS GroupBoost TargetBuy ➝ Buy$22.00 ➝ $24.00
7/10/2024ArgusUpgradeHold ➝ Buy$20.00
6/27/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$19.00 ➝ $23.00
6/5/2024BarclaysBoost TargetOverweight ➝ Overweight$20.00 ➝ $21.00
5/30/2024Bank of AmericaBoost TargetBuy ➝ Buy$18.00 ➝ $21.00
5/13/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$19.00 ➝ $20.00
5/9/2024BarclaysBoost TargetOverweight ➝ Overweight$17.00 ➝ $20.00
3/8/2024JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$14.00
2/12/2024Piper SandlerUpgradeNeutral ➝ Overweight$12.00 ➝ $19.00
2/5/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$10.00 ➝ $11.00
2/5/2024BarclaysBoost TargetOverweight ➝ Overweight$15.00 ➝ $17.00
1/29/2024BarclaysBoost TargetOverweight ➝ Overweight$14.00 ➝ $15.00
1/23/2024Jefferies Financial GroupUpgradeHold ➝ Buy$10.00 ➝ $14.00
1/3/2024Piper SandlerUpgradeUnderweight ➝ Neutral$8.00 ➝ $12.00
12/18/2023HSBCInitiated CoverageBuy$13.00
11/27/2023UBS GroupUpgradeNeutral ➝ Buy$11.00 ➝ $13.00
9/20/2023UBS GroupBoost TargetNeutral ➝ Neutral$8.00 ➝ $11.00
9/8/2023Bank of AmericaBoost TargetBuy ➝ Buy$12.00 ➝ $13.00
7/6/2023UBS GroupUpgradeSell ➝ Neutral$7.00 ➝ $8.00
5/25/2023Morgan StanleyInitiated CoverageEqual Weight$10.00
5/18/2023EvercoreUpgradeIn-Line ➝ Outperform
2/9/2023BarclaysBoost TargetOverweight$13.00 ➝ $14.00
1/19/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$10.00 ➝ $12.00
11/23/2022Piper SandlerLower TargetUnderweight$8.00 ➝ $7.00
11/14/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$11.00 ➝ $10.00
11/7/2022BMO Capital MarketsLower TargetMarket Perform$11.00 ➝ $10.00
11/4/2022UBS GroupDowngradeNeutral ➝ Sell
10/21/2022Jefferies Financial GroupReiterated RatingBuy$10.00
8/5/2022Bank of AmericaUpgradeNeutral ➝ Buy$10.00 ➝ $13.00
8/2/2022The Goldman Sachs GroupBoost TargetNeutral$9.00 ➝ $10.00
6/13/2022UBS GroupInitiated CoverageNeutral$10.00
5/17/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$9.00
5/4/2022Piper SandlerDowngradeNeutral ➝ Underweight$11.00 ➝ $7.00
4/5/2022BarclaysUpgradeEqual Weight ➝ Overweight$11.00 ➝ $13.00
3/25/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$11.00
2/18/2022BarclaysLower TargetEqual Weight$13.00 ➝ $11.00
1/27/2022ArgusDowngradeBuy ➝ Hold
10/28/2021Raymond James FinancialDowngradeOutperform ➝ Market Perform
7/29/2021Raymond James FinancialLower TargetOutperform$15.00 ➝ $14.00
7/29/2021Wells Fargo & CompanyLower TargetEqual Weight$12.00 ➝ $11.00
5/10/2021UBS GroupReiterated RatingBuy ➝ Neutral$15.00 ➝ $11.00
5/4/2021UBS GroupDowngradeBuy ➝ Neutral$15.00 ➝ $11.00
3/14/2021JPMorgan Chase & Co.Reiterated RatingHold$10.00
(Data available from 3/5/2021 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 6 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 6 very positive mentions
  • 16 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
10/6/2025
  • 7 very positive mentions
  • 8 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2025
  • 10 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025
  • 13 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
1/4/2026
  • 8 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 38 very positive mentions
  • 12 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
Mentions as of
3/5/2026

Current Sentiment

  • 38 very positive mentions
  • 12 positive mentions
  • 8 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Read More

Today's Range

Now: $32.87
Low: $32.03
High: $33.30

50 Day Range

MA: $33.03
Low: $30.94
High: $36.25

52 Week Range

Now: $32.87
Low: $12.47
High: $37.35

Volume

9,421,266 shs

Average Volume

6,711,075 shs

Market Capitalization

$37.79 billion

P/E Ratio

27.39

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Teva Pharmaceutical Industries?

The following sell-side analysts have issued research reports on Teva Pharmaceutical Industries in the last year: Bank of America Corporation, Barclays PLC, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, Scotiabank, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for TEVA.

What is the current price target for Teva Pharmaceutical Industries?

0 Wall Street analysts have set twelve-month price targets for Teva Pharmaceutical Industries in the last year. Their average twelve-month price target is $37.67, suggesting a possible upside of 14.6%. The Goldman Sachs Group, Inc. has the highest price target set, predicting TEVA will reach $45.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $26.00 for Teva Pharmaceutical Industries in the next year.
View the latest price targets for TEVA.

What is the current consensus analyst rating for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries currently has 1 sell rating, 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TEVA.

What other companies compete with Teva Pharmaceutical Industries?

Other companies that are similar to Teva Pharmaceutical Industries include GSK, Sanofi, Takeda Pharmaceutical, argenex and BeOne Medicines. Learn More about companies similar to Teva Pharmaceutical Industries.

How do I contact Teva Pharmaceutical Industries' investor relations team?

Teva Pharmaceutical Industries' physical mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company's listed phone number is (723) 914-8213 and its investor relations email address is [email protected]. The official website for Teva Pharmaceutical Industries is www.tevapharm.com. Learn More about contacing Teva Pharmaceutical Industries investor relations.